TY - JOUR
T1 - Digital health technologies in the accelerating medicines Partnership® Schizophrenia Program
AU - Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ)
AU - Wigman, Johanna T.W.
AU - Ching, Ann Ee
AU - Chung, Yoonho
AU - Eichi, Habiballah Rahimi
AU - Lane, Erlend
AU - Langholm, Carsten
AU - Vaidyam, Aditya
AU - Byun, Andrew Jin Soo
AU - Haidar, Anastasia
AU - Hartmann, Jessica
AU - Nunez, Angela
AU - Dwyer, Dominic
AU - Nasarudin, Adibah Amani
AU - Borders, Owen
AU - Scott, Isabelle
AU - Tamayo, Zailyn
AU - Matneja, Priya
AU - Cho, Kang Ik
AU - Addington, Jean
AU - Alameda, Luis K.
AU - Arango, Celso
AU - Breitborde, Nicholas J.K.
AU - Broome, Matthew R.
AU - Cadenhead, Kristin S.
AU - Calkins, Monica E.
AU - Chen, Eric Yu Hai
AU - Choi, Jimmy
AU - Conus, Philippe
AU - Corcoran, Cheryl M.
AU - Cornblatt, Barbara A.
AU - Diaz-Caneja, Covadonga M.
AU - Ellman, Lauren M.
AU - Fusar-Poli, Paolo
AU - Gaspar, Pablo A.
AU - Gerber, Carla
AU - Glenthøj, Louise Birkedal
AU - Horton, Leslie E.
AU - Hui, Christy Lai Ming
AU - Kambeitz, Joseph
AU - Kambeitz-Ilankovic, Lana
AU - Keshavan, Matcheri S.
AU - Kim, Sung Wan
AU - Koutsouleris, Nikolaos
AU - Langbein, Kerstin
AU - Mamah, Daniel
AU - Mathalon, Daniel H.
AU - Mittal, Vijay A.
AU - Nordentoft, Merete
AU - Pearlson, Godfrey D.
AU - Bouix, Sylvain
N1 - Publisher Copyright:
© The Author(s) 2025.
PY - 2025/12
Y1 - 2025/12
N2 - Although meta-analytic studies have shown that 25-33% of those at Clinical High Risk (CHR) for psychosis transition to a first episode of psychosis within three years, less is known about estimating the risk of transition at an individual level. Digital phenotyping offers a novel approach to explore the nature of CHR and may help to improve personalized risk prediction. Specifically, digital data enable detailed mapping of experiences, moods and behaviors during longer periods of time (e.g., weeks, months) and offer more insight into patterns over time at the individual level across their routine daily life. However, while novel digital health technologies open up many new avenues of research, they also come with specific challenges, including replicability of results and the adherence of participants. This paper outlines the design of the digital component of the Accelerating Medicines Partnership® Schizophrenia Program (AMP SCZ) project, a large international collaborative project that follows individuals at CHR for psychosis over a period of two years. The digital component comprises one-year smartphone-based digital phenotyping and actigraphy. Smartphone-based digital phenotyping includes 30-item short daily self-report surveys and voice diaries as well as passive data capture (geolocation, on/off screen state, and accelerometer). Actigraphy data are collected via an Axivity wristwatch. The aim of this paper is to describe the design and the three goals of the digital measures used in AMP SCZ to: (i) better understand the symptoms, real-life experiences, and behaviors of those at CHR for psychosis, (ii) improve the prediction of transition to psychosis and other health outcomes in this population based on digital phenotyping and, (iii) serve as an example for replicable and ethical research across geographically diverse regions and cultures. Accordingly, we describe the rationale, protocol and implementation of these digital components of the AMP SCZ project. **Link to video interview: https://vimeo.com/1060935583**
AB - Although meta-analytic studies have shown that 25-33% of those at Clinical High Risk (CHR) for psychosis transition to a first episode of psychosis within three years, less is known about estimating the risk of transition at an individual level. Digital phenotyping offers a novel approach to explore the nature of CHR and may help to improve personalized risk prediction. Specifically, digital data enable detailed mapping of experiences, moods and behaviors during longer periods of time (e.g., weeks, months) and offer more insight into patterns over time at the individual level across their routine daily life. However, while novel digital health technologies open up many new avenues of research, they also come with specific challenges, including replicability of results and the adherence of participants. This paper outlines the design of the digital component of the Accelerating Medicines Partnership® Schizophrenia Program (AMP SCZ) project, a large international collaborative project that follows individuals at CHR for psychosis over a period of two years. The digital component comprises one-year smartphone-based digital phenotyping and actigraphy. Smartphone-based digital phenotyping includes 30-item short daily self-report surveys and voice diaries as well as passive data capture (geolocation, on/off screen state, and accelerometer). Actigraphy data are collected via an Axivity wristwatch. The aim of this paper is to describe the design and the three goals of the digital measures used in AMP SCZ to: (i) better understand the symptoms, real-life experiences, and behaviors of those at CHR for psychosis, (ii) improve the prediction of transition to psychosis and other health outcomes in this population based on digital phenotyping and, (iii) serve as an example for replicable and ethical research across geographically diverse regions and cultures. Accordingly, we describe the rationale, protocol and implementation of these digital components of the AMP SCZ project. **Link to video interview: https://vimeo.com/1060935583**
UR - https://www.scopus.com/pages/publications/105009256735
U2 - 10.1038/s41537-025-00599-w
DO - 10.1038/s41537-025-00599-w
M3 - Journal Article
AN - SCOPUS:105009256735
SN - 2754-6993
VL - 11
JO - Schizophrenia
JF - Schizophrenia
IS - 1
M1 - 83
ER -